Similar articles

• Prostate specific antigen and screening for early prostate cancer.

  Davidson P. Davidson P. N Z Med J. 2001 Apr 13;114(1129):150. N Z Med J. 2001. PMID: 11400919 No abstract available.
• Prostate cancer: screening and treatment options.

  Horger DC, Clarke HS. Horger DC, et al. J S C Med Assoc. 2003 Apr;99(4):85-7. J S C Med Assoc. 2003. PMID: 12762154 Review. No abstract available.
• Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.

  Hamilton RJ, Platz EA, Freedland SJ. Hamilton RJ, et al. J Natl Cancer Inst. 2009 Apr 15;101(8):611-2. doi: 10.1093/jnci/djp043. Epub 2009 Apr 7. J Natl Cancer Inst. 2009. PMID: 19351913 No abstract available.
• Rotterdam randomized pilot studies of screening for prostate cancer--an overview after 10 years.

  Schröder FH, Roobol MJ, Damhuis RA, de Koning HJ, Blijenberg BG, Van der Kwast TH, Kirkels WJ, Bangma CH. Schröder FH, et al. J Natl Cancer Inst. 2005 May 4;97(9):696. doi: 10.1093/jnci/dji121. J Natl Cancer Inst. 2005. PMID: 15870441 No abstract available.
• Impact of prostate-specific antigen screening on the natural history of prostate cancer.

  Rosen MA. Rosen MA. Urology. 1995 Dec;46(6):757-68. doi: 10.1016/S0090-4295(99)80339-2. Urology. 1995. PMID: 7502411 Review. No abstract available.